Kanabo Research develops, medically validates, and patents formulations of medical cannabis extracts designed to target specific Central Nervous System (CNS) disorders. The first formulations under development focus on sleep disorders, chronic pain, and anxiety disorders with a special focus on post-traumatic stress disorder. Kanabo’s formulations provide the precision and consistency of clinical validation along with the benefits of therapeutic botanical compounds.
Kanabo Research conducts clinical validation activities in Israel for all technology and formulations under development, to ensure safety and efficacy of all company products. Kanabo’s VapePod® vaporizer platform was granted initial certification as a medical device by the Israeli Ministry of Health, making it the first extract based vaporizer approved for medical use. Kanabo also initiated pre-clinical trials on their first patented formulation, and is achieving impressive results in early findings.
VapePod®, Kanabo Research’s medical grade delivery system, is the first approved medical device of its kind, approved by the Israeli Ministry of Health as a medical device for inhalation. Kanabo partnered with a US-based vaporizer company to develop the high-quality, safe, and dosable vaporizer platform. The sophisticated design and CCELL ceramic core technology ensures superior vapor performance – providing a safe, consistent, and trustworthy user experience.